Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin‐fixed breast carcinoma cell block preparations: Correlation of results to corresponding tissue block (needle core and excision) samples
- 21 May 2012
- journal article
- research article
- Published by Wiley in Diagnostic Cytopathology
- Vol. 41 (3) , 192-198
Abstract
Evaluation of ER, PR and Her 2 are routinely performed on breast carcinomas. For accurate detection of these markers, compliance with the ASCO/CAP guidelines is recommended.Our previous study showed that alcohol fixation did not affect ER results when alcohol‐fixed cell block (CB) sections were compared to formalin‐fixed tissue sections, while PR and Her2 showed less concordance.The aim of this study was to evaluate and to compare ER, PR and Her2 IHC results on formalin‐fixed CB sections to those observed on subsequent surgical (needle core or resection) specimens (SS).Fifty cases of formalin fixed CB samples obtained from primary (18%) and metastatic (82%) breast carcinomas were studied, all of which had subsequent SS available. ER, PR, and Her2 IHC studies were done on all samples and results were compared.ER results on formalin‐fixed CB samples showed excellent correlation with SS (correlation coefficient cc = 0.82). While there was minimal improvement in PR results (cc = 0.433), Her2 detection did not improve by formalin fixation (cc = 0.439). Formalin fixation for CB preparations does not significantly improve the already good detection of ER positive breast tumors. The concordance rate in PR and IHC results between formalin‐fixed CB and SS samples showed improvement as compared with the alcohol‐fixed CB results. However, there was no improvement in detection of Her2 overexpression by using formalin fixation on cytology specimens. Diagn. Cytopathol. 2013.Keywords
This publication has 15 references indexed in Scilit:
- Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinomaDiagnostic Cytopathology, 2011
- NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by ImmunohistochemistryJournal of the National Comprehensive Cancer Network, 2009
- Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysisDiagnostic Cytopathology, 2009
- High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring systemLaboratory Investigation, 2008
- Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapyThe Breast, 2005
- Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine TherapyJournal of Clinical Oncology, 2005
- Minimum Formalin Fixation Time for Consistent Estrogen Receptor Immunohistochemical Staining of Invasive Breast CarcinomaAmerican Journal of Clinical Pathology, 2003
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Effect of Formalin Tissue Fixation and Processing on ImmunohistochemistryAmerican Journal of Surgical Pathology, 2000